We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Advanced Imaging Reveals Mechanisms Causing Autoimmune Disease

By LabMedica International staff writers
Posted on 11 Apr 2025

Myasthenia gravis, an autoimmune disease, leads to muscle weakness that can affect a range of muscles, including those needed for basic actions like blinking, smiling, or moving. More...

Researchers have long understood that the condition arises from miscommunication between the nerves and muscles. The immune system mistakenly generates autoantibodies, which are antibodies that attack the body’s own tissues and proteins. In myasthenia gravis, these autoantibodies specifically target acetylcholine receptors (AChRs), which are crucial for initiating normal muscle contractions. While medications aimed at boosting acetylcholine levels and suppressing the immune system can offer relief, their effectiveness varies, leading researchers to hypothesize that the disease may involve different underlying mechanisms in different individuals.

In a collaborative effort, scientists from UC San Diego (La Jolla, CA, USA) and Yale University (New Haven, CT, USA) employed advanced cryo-electron microscopy (cryo-EM) to examine the structure of human muscle AChRs in great detail. Their findings, published in the journal Cell, focused on analyzing the autoantibodies from six distinct myasthenia gravis patients. They found that these autoantibodies disrupt the normal functioning of AChRs in several ways. Some antibodies block the binding process of acetylcholine, while others activate the immune system’s complement pathway, leading to the destruction of the receptors. Crucially, all the autoantibodies directly impair the receptor’s ability to function as an ion channel. These discoveries challenge prior beliefs about how myasthenia gravis antibodies interfere with receptor activity.

The researchers suggest that future treatments for myasthenia gravis could focus on targeting specific antibody interactions, rather than relying solely on general immunosuppression therapies. To conduct their study, they gathered blood samples from patients and used cell-based functional assays to explore the harmful properties of the autoantibodies. They also performed high-resolution structural studies and electrophysiological experiments to understand how these antibodies interact with and disrupt the function of AChRs. This collaborative research emphasizes the growing importance of personalized medicine and demonstrates how partnerships between institutions can drive breakthroughs that have direct clinical implications.

“By mapping antibody binding sites on the receptor, we revealed a surprising diversity in how autoantibodies contribute to myasthenia gravis. This knowledge helps explain why some patients respond differently to treatments and provides a foundation for developing more personalized therapies,” said Neurobiology Professor Ryan Hibbs, the study’s senior author. “This study not only advances our understanding of myasthenia gravis but also sheds light on other autoimmune diseases in which antibodies attack ion channels, offering hope for more precise and effective treatment strategies.”

Related Links:
UC San Diego
Yale University


Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Rapid Molecular Testing Device
FlashDetect Flash10
New
6 Part Hematology Analyzer with RET + IPF
Mispa HX 88
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The ONC IN-CYT platform leverages cross indication biomarker cyto-signatures (Photo courtesy of OraLiva)

AI-Powered Cytology Tool Detects Early Signs of Oral Cancer

Each year, 54,000 Americans are diagnosed with oral cancer, yet only 28% of cases are identified at an early stage, when the five-year survival rate exceeds 85%. Most diagnoses occur in later stages, when... Read more

Hematology

view channel
Image: The microfluidic device for passive separation of platelet-rich plasma from whole blood (Photo courtesy of University of the Basque Country)

Portable and Disposable Device Obtains Platelet-Rich Plasma Without Complex Equipment

Platelet-rich plasma (PRP) plays a crucial role in regenerative medicine due to its ability to accelerate healing and repair tissue. However, obtaining PRP traditionally requires expensive centrifugation... Read more

Immunology

view channel
Image: PD-1 protein blockade is the standard treatment for advanced melanoma among the different types of immunotherapy (Photo courtesy of 123RF)

Precision Tool Predicts Immunotherapy Treatment Failure in Melanoma Patients

Melanoma, though accounting for only about 4% of skin tumors, is the deadliest form of skin cancer due to its high potential to metastasize. While immunotherapy, especially PD-1 protein blockade, has revolutionized... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.